- Brazil
- /
- Healthcare Services
- /
- BOVESPA:FLRY3
Fleury Third Quarter 2024 Earnings: Revenues Miss Expectations
Fleury (BVMF:FLRY3) Third Quarter 2024 Results
Key Financial Results
- Revenue: R$1.96b (up 5.0% from 3Q 2023).
- Net income: R$190.7m (up 9.5% from 3Q 2023).
- Profit margin: 9.7% (in line with 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fleury Revenues Disappoint
Revenue missed analyst estimates by 1.1%.
Looking ahead, revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Healthcare industry in Brazil.
Performance of the Brazilian Healthcare industry.
The company's shares are down 4.5% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Fleury you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:FLRY3
Fleury
Provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil.
Undervalued with solid track record and pays a dividend.